Cancer Testing

At Mekoshaa Alami, we’re transforming the way cancer is detected with our groundbreaking, non-invasive blood test. Imagine being able to detect up to 70 types of solid organ cancers—often before any symptoms show up. This isn’t just a test; it’s a game-changer for those managing conditions like diabetes, COPD, or a family history of cancer. Early detection is your most powerful weapon, and with our advanced technology, we’re making it easier than ever.

Our innovative test homes in on Circulating Tumor Cells (CTCs)—tiny signals that are nearly invisible in healthy people but can indicate the early presence of cancer. All it takes is a simple blood draw, and you could be on the path to a healthier future, catching potential issues before they become major concerns. With Mekoshaa Alami, you’re not just getting a test; you’re gaining peace of mind and taking a proactive step towards your health. Don’t wait for symptoms—be ahead of the curve with us.

Screening

His advanced blood test offers a non-invasive, accurate, and cost-effective approach for early cancer screening. It can detect the presence of malignancy in individuals without symptoms or those at high risk of developing cancer. By analyzing circulating tumor cells in the blood, the test provides early detection of solid and brain tumors, allowing for timely intervention. With its high sensitivity and specificity, it serves as a valuable tool for identifying cancer at an early stage, reducing the need for invasive screening methods and helping to improve patient outcomes.

Inquire now

Diagnosis

Non-Invasive Blood-Based Diagnostic Tool for Cancer
It is particularly useful for:

Symptomatic individuals recommended for invasive tissue biopsy to assess malignancy Cases where biopsy results are inconclusive or inconsistent with clinical findings. Suspected metastatic relapse, to rule out a new primary tumor. With high sensitivity (99.8% and 95.4%), the test isolates and analyzes live circulating tumor cells from a simple blood sample. A positive result helps clinicians determine the need for further invasive procedures. Clinically validated through extensive research, this test is a transformative tool in cancer diagnostics, offering reliable triaging for solid and brain tumors.

Inquire now

Monitoring

When first-line therapy fails, cancer relapses, or the cancer is high-grade/metastatic, genomic profiling is used to guide treatment for difficult-to-treat cancers or those lacking a standard of care. This includes analyzing targeted genes (SNVs, CNVs, Indels), tumor mutation burden, germline mutations, RNA (KEGG pathways, gene expression, fusion/rearrangement), and pharmacogenetics (CYP450 genotyping for drug toxicity/efficacy). Chemosensitivity testing and protein marker analysis (IHC/ICC) are also performed to optimize therapy selection.

Inquire now

Treatment

Advanced genomic profiling is crucial for selecting personalized cancer therapies, including targeted and immunotherapies based on genetic and molecular traits.

Targeted Therapy: A comprehensive analysis of 511 genes for therapy selection, aligned with NCCN guidelines, with ≥1000x coverage depth.

Immunotherapy: Evaluates MSI, TMB, PD-L1 (22C3, 28-8, SP 142) for NSCLC and Urothelial cancer, with access to relevant clinical trials.

Non-invasive liquid biopsy detects cancer biomarkers in the blood, providing real-time molecular profiling to monitor disease progression, recurrence, and treatment resistance. It offers a faster, safer alternative to traditional methods without radiation or surgery.

Inquire now
×